{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:37Z","timestamp":1791827497527,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      First-line treatment options for\n                      <jats:italic>HER2<\/jats:italic>\n                      -altered advanced non-small cell lung cancer (NSCLC) remain limited, especially in cases with\n                      <jats:italic>HER2-EGFR<\/jats:italic>\n                      co-alterations. While new agents like trastuzumab deruxtecan (T-DXd) have emerged, its real-world evidence in first line remains limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included patients with advanced NSCLC who had HER2 mutations or amplification and received first-line systemic therapy at six medical centers. Outcomes were evaluated following chemotherapy-based combinations, pan-HER tyrosine kinase inhibitors (TKIs), and T-DXd. Endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), one-year and two-year survival rates, and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 69 patients were enrolled, comprising 45 with only\n                      <jats:italic>HER2<\/jats:italic>\n                      alterations and 24 with\n                      <jats:italic>HER2<\/jats:italic>\n                      -\n                      <jats:italic>EGFR<\/jats:italic>\n                      co-alterations. In patients with only\n                      <jats:italic>HER2<\/jats:italic>\n                      -altered NSCLC, those receiving first-line T-DXd had an mPFS of 15.7 months (95% CI, 12.5\u201318.9), an ORR of 85.7%, and a DCR of 100.0%. The mPFS for patients receiving chemotherapy-based regimens, pan-HER TKIs, and chemotherapy plus pan-HER TKIs were 7.6 (95% CI, 6.6\u20138.5) months, 4.4 (95% CI, 4.0-4.9) months, and 7.0 (95% CI, 6.1\u20139.1) months, respectively. The ORR for the three groups above was 33.3%, 0, and 0, respectively. In subgroup analysis, patients with only\n                      <jats:italic>HER2<\/jats:italic>\n                      alterations who did not harbor\n                      <jats:italic>TP53<\/jats:italic>\n                      mutations had a longer PFS than those with\n                      <jats:italic>TP53<\/jats:italic>\n                      co-mutations (8.7\u00a0m vs. 7.2\u00a0m; HR: 0.35; 95% CI: 0.11\u20130.99;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048). In patients with\n                      <jats:italic>EGFR-HER2<\/jats:italic>\n                      co-alterations, first-line EGFR-TKI monotherapy yielded an mPFS of 9.7 (95% CI, 8.6\u201310.8) months, an ORR of 40.0%, and a DCR of 93.3%. Regarding safety, we did not observe Grade\u2009\u2265\u20093 TRAEs in first-line T-DXd treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      First-line T-DXd showed promising activity signals in only\n                      <jats:italic>HER2<\/jats:italic>\n                      -altered NSCLC. In\n                      <jats:italic>EGFR-HER2<\/jats:italic>\n                      co-altered patients, the EGFR-TKI monotherapy showed limited efficacy. The findings underscored the urgent need for prospective randomised trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16688-7","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:29:51Z","timestamp":1791826191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2\/EGFR co-alteration status"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-9870","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-4794","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-yu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-7194","authenticated-orcid":false,"given":"Zhe-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-7060","authenticated-orcid":false,"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-5692","authenticated-orcid":false,"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"16688_CR1","doi-asserted-by":"crossref","unstructured":"Cheng X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes (Basel). 2024;15(7):903.","DOI":"10.3390\/genes15070903"},{"issue":"16","key":"16688_CR2","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","volume":"31","author":"J Mazi\u00e8res","year":"2013","unstructured":"Mazi\u00e8res J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin oncology: official J Am Soc Clin Oncol. 2013;31(16):1997\u20132003.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"5","key":"16688_CR3","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00432-022-04196-7","volume":"149","author":"X Zhuo","year":"2023","unstructured":"Zhuo X, Guo H, Ma J, Lai J, Liu L, Yin K, Zhao J, Wang J, Jiang F, Xu W, et al. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations. J Cancer Res Clin Oncol. 2023;149(5):2029\u201339.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"16688_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"Cancer J Clin"},{"issue":"5","key":"16688_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. Cancer J Clin. 2022;72(5):409\u201336.","journal-title":"Cancer J Clin"},{"issue":"1","key":"16688_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1759-7714.14743","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, et al. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer. Thorac cancer. 2023;14(1):91\u2013104.","journal-title":"Thorac cancer"},{"issue":"9","key":"16688_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Wood DE, Aisner DL, Loo BW Jr., Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, et al. NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 7.2025. J Natl Compr Cancer Network: JNCCN. 2025;23(9):354\u201362.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"1","key":"16688_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1186\/s12885-024-12748-y","volume":"24","author":"H Qin","year":"2024","unstructured":"Qin H, Yan H, Chen Y, Xu Q, Huang Z, Jiang W, Wang Z, Deng L, Zhang X, Zhang L, et al. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations. BMC Cancer. 2024;24(1):952.","journal-title":"BMC Cancer"},{"issue":"1","key":"16688_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","volume":"15","author":"U Gatzemeier","year":"2004","unstructured":"Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Annals oncology: official J Eur Soc Med Oncol. 2004;15(1):19\u201327.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"20","key":"16688_CR10","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-07-0460","volume":"13","author":"RS Herbst","year":"2007","unstructured":"Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin cancer research: official J Am Association Cancer Res. 2007;13(20):6175\u201381.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"16688_CR11","doi-asserted-by":"publisher","first-page":"657283","DOI":"10.3389\/fonc.2021.657283","volume":"11","author":"Z Song","year":"2021","unstructured":"Song Z, Lv D, Chen S, Huang J, Wang L, Xu S, Chen H, Wang G, Lin Q. Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study. Front Oncol. 2021;11:657283.","journal-title":"Front Oncol"},{"issue":"8","key":"16688_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cncr.28561","volume":"120","author":"KL Reckamp","year":"2014","unstructured":"Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145\u201354.","journal-title":"Cancer"},{"key":"16688_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","volume":"162","author":"E Iwama","year":"2022","unstructured":"Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, Sakamoto T, Murakami H, Kishimoto J, Matsumoto S, et al. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. Eur J cancer (Oxford England: 1990). 2022;162:99\u2013106.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"17","key":"16688_CR14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa2516969","volume":"394","author":"JV Heymach","year":"2026","unstructured":"Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, et al. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026;394(17):1675\u201384.","journal-title":"N Engl J Med"},{"issue":"3","key":"16688_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-025-02265-y","volume":"86","author":"A Lee","year":"2026","unstructured":"Lee A. Zongertinib: First Approval. Drugs. 2026;86(3):397\u2013401.","journal-title":"Drugs"},{"issue":"5","key":"16688_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40265-026-02299-w","volume":"86","author":"SJ Keam","year":"2026","unstructured":"Keam SJ. Sevabertinib: First Approval. Drugs. 2026;86(5):759\u201364.","journal-title":"Drugs"},{"issue":"12","key":"16688_CR17","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","volume":"20","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, P\u00e9rol M, et al. Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC. J Thorac oncology: official publication Int Association Study Lung Cancer. 2025;20(12):1814\u201328.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"16688_CR18","doi-asserted-by":"publisher","first-page":"102393","DOI":"10.1016\/j.ctrv.2022.102393","volume":"106","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;106:102393.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"16688_CR19","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/2159-8290.CD-NB2022-0053","volume":"12","author":"FDA Gives","year":"2022","unstructured":"FDA Gives. Nod to T-DXd for HER2-Mutant NSCLC. Cancer Discov. 2022;12(10):2224.","journal-title":"Cancer Discov"},{"issue":"7Supplement","key":"16688_CR20","doi-asserted-by":"publisher","first-page":"CT248","DOI":"10.1158\/1538-7445.AM2024-CT248","volume":"84","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wu L, Fang Y, Fan Y, Li X, Zhang M, Yu Y, Yao Y, Xu R, Guo J, et al. Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Res. 2024;84(7Supplement):CT248\u2013248.","journal-title":"Cancer Res"},{"issue":"1","key":"16688_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jtho.2019.09.006","volume":"15","author":"CC Hsu","year":"2020","unstructured":"Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JC. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R\/T790M-Positive Non-Small Cell Lung Cancer. J Thorac oncology: official publication Int Association Study Lung Cancer. 2020;15(1):50\u201361.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"issue":"2","key":"16688_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"21","key":"16688_CR23","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"16688_CR24","doi-asserted-by":"publisher","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","volume":"6","author":"M Riudavets","year":"2021","unstructured":"Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6(5):100260.","journal-title":"ESMO Open"},{"key":"16688_CR25","doi-asserted-by":"publisher","first-page":"1564834","DOI":"10.3389\/fphar.2025.1564834","volume":"16","author":"G Huang","year":"2025","unstructured":"Huang G, Xia T, Yang D, Lin M, Luo Y, Li Y, Chen H. Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights. Front Pharmacol. 2025;16:1564834.","journal-title":"Front Pharmacol"},{"key":"16688_CR26","doi-asserted-by":"publisher","first-page":"107327482513475","DOI":"10.1177\/10732748251347572","volume":"32","author":"C Liu","year":"2025","unstructured":"Liu C, Li T, Cui X, Lv Y, Liu M, Zhou X, Yang F, Dong Y, Li R, Zhang F, et al. Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China. Cancer control: J Moffitt Cancer Cent. 2025;32:10732748251347572.","journal-title":"Cancer control: J Moffitt Cancer Cent"},{"key":"16688_CR27","unstructured":"Riely GJ, Wood DE, Aisner DL, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J et al. Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(4):e260017."},{"issue":"1","key":"16688_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","volume":"9","author":"X Bai","year":"2023","unstructured":"Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, et al. Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discov. 2023;9(1):18.","journal-title":"Cell Discov"},{"issue":"1","key":"16688_CR29","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1038\/s41467-024-47606-9","volume":"15","author":"S Hobor","year":"2024","unstructured":"Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024;15(1):4871.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16688-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:29:53Z","timestamp":1791826193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16688-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16688"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16688-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of the PLA General Hospital of China approved this study in accordance with the ethical standards of the Declaration of Helsinki and its subsequent amendments. Ethical approval for this retrospective study was granted by the institutional review boards (IRBs) of all participating Medical Centers of PLAGH, understanding that the study poses minimal risk to patients and involves the analysis of existing data. Given the study\u2019s retrospective nature and the use of de-identified data, the IRB of PLAGH provided a waiver for the requirement of written informed consent (Ethical Approval Number: [S2024-794]).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1220"}}